The problem of resistant Trichomonas vaginalis to antiprotozoal drugs
https://doi.org/10.22625/2072-6732-2011-3-4-34-43
Abstract
This review presents recent data on the energy metabolism of Trichomonas vaginalis and ways the activation of metronidazole. The sensitivity of microorganisms to the 5-nitroimidazole by the presence of their enzyme systems, generating and transporting electrons, which can then transfer them to the nitro group of the drug. In T.vaginalis these are pyruvate ferredoxin-oxydoreductase, thioredoxin reductase and flavin reductase. The development of resistance T.vaginalis to metronidazole preparations of this multistep process, based on the gradual reduction (up to a loss) activity hydrogenosomal enzymes and / or violation of the flavindependent metabolic pathways.
About the Authors
A. L. PoznyakRussian Federation
S. S. Kozlov
Russian Federation
R. V. Gudkov
Russian Federation
Yu. F. Zaharkiv
Russian Federation
S. N. Sidorchuk
Russian Federation
O. L. Molchanov
Russian Federation
References
1. Lossick J. G. In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractoryvaginal trichomoniasis / J.G. Lossick, M. Muller, T. E. Gorrell // J.Infect.Dis. – 1986. – Vol. 153, № 5. – Р. 948–955.
2. Lossick J. G. Trichomoniasis: trends in diagnosis and management / J.G. Lossick, H.L. Kent // Am.J.Obstet. Gynecol. – 1991. – Vol.165, №5. – Р. 1217–1222.
3. Pereyra A. J. Flunidazole – a new drug for systemic treatment of urogenital trichomoniasis / A.J. Pereyra, R.M. Nelson, D.J. Ludders // Am. J. Obstet. Gynecol. – 1972. – Vol. 112. – Р. 963–966.
4. Debbia E.A. In vitro activity of metronidazole alone and in combination with clotrimazole against clinical isolates of Trichomonas vaginalis. / E.A. Debbia, U. Campora, S. Massaro et al. // J. Chemother. – 1996. Vol. 8, № 2. – P. 96–101.
5. Du Bouchet L. Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis /L. Du Bouchet, M.R. Spence, M.F. Rein et al. // Sex. Transm. Dis. – 1997. – Vol. 24, №3.– P.156–160.
6. Cosar C. Activity of 1-(29-hydroxyethyl)-2-methyl-5-nitroimidazole (8823 RP) against experimental Trichomonas vaginalis infection / C. Cosar, L. Julou // Ann. Inst. Pasteur. – 1959. – An.96 – P. 238–241.
7. Chaudhuri P. A double-blind controlled clinical trial of carnidazole and tinidazole in the treatment of vaginal trichomoniasis / P. Chaudhuri, A.C. Drogendijk // Eur.J.Obstet. Gynecol. – 1980. – Vol. 10, № 5. – P. 325–328.
8. Fugere P. Single oral dose of ornidazole in women with vaginal trichomoniasis / P. Fugere, G. Verschelden, M. Caron //Obstet. Gynecol.- 1983. – Vol. 62, №4. – P. 502–505.
9. Hayward M.J. Two-day treatment of trichomoniasis in the female. Comparison of metronidazole and nimorazole /M.J. Hayward, R.B. Roy // Br.J.Vener.Dis. – 1976. – Vol. 52, № 1. – P. 63–64.
10. Pereyra A.J. Flunidazole—a new drug for systemic treatment of urogenital trichomoniasis / A.J. Pereyra, R.M. Nelson, D.J. Ludders // Am.J.Obstet.Gynecol. – 1972. – Vol. 112, № 7. – P. 963–966.
11. Sucharit P. In vivo and in vitro studies of tinidazole in Trichomonas vaginalis infection / P. Sucharit, A. Uthaischant, T. Chintana // S.E.Asian J. Trop. Med. Public Health. – 1979. – Vol. 10, №4. – P. 556–561.
12. Videau D. Secnidazole. A 5-nitroimidazole derivative with a long half-life / D. Videau, G. Niel, A. Siboulet // Br.J.Vener. Dis. – 1978. – Vol. 54, № 2. – P. 77–80.
13. Freeman C.D. Metronidazole. A therapeutic review and update / C. D. Freeman, N.E. Klutman, K.C. Lamp // Drugs. – 1997. – Vol. 54, № 5. – P. 679–708.
14. Ravdin J.I. Amebiasis. State-of-the-art clinical article /Ravdin J.I. // Clin.Infect.Dis. – 1995. – Vol. 20. – P. 1453–1464.
15. Zaat J.O. A systematic review on the treatment of giardiasis / J.O. Zaat, T.G. Mank, W.J. Assendelft // Trop.Med. Int.Health. – 1997. – Vol. 2, № 1. – P. 63–82.
16. Shinn D.L. Metronidazole in acute ulcerative gingivitis /Shinn D.L. // Lancet. – 1962. – №1. – P. 1191.
17. Lau A.H. Clinical pharmokinetics of metronidazole and other nitroimidazole antiinfectives / A.H. Lau, N.P. Lam, S.C. Piscitelli // Clin. Pharmacokinet.- 1992. – Vol. 23, № 5. – P. 328–364.
18. Падейская Е.Н. Препараты группы 5-нитроимидазола для лечения анаэробных и протозойных инфекций /Е.Н. Падейская Е.Н. // Инфекции и антимикробная терапия. – 2000. – Т. 2, № 4. – С. 4–7.
19. Mertens M. Presence of a fructose-2,6-bisphosphateinsensitive pyrophosphate: fructose-6-phosphate phos photransferase in the anaerobic protozoa Tritrichomonas foetus, Trichomonas vaginalis and Isotricha prostoma / M. Mertens, E.Van Schaftingen, M. Muller // Mol.Biochem.Parasitol. – 1989. – Vol. 37, № 2. – P. 183–190.
20. Hrdý I. Identification, purification and separation of different isozymes of NADP-specific malic enzyme from Tritrichomonas foetus / I. Hrdý, E. Mertensa, E. Van Schaftingen // Mol.Biochem.Parasitol. – 1993. – Vol. 57, №2. – P. 253–260.
21. Drmota T. Iron-ascorbate cleavable malic enzyme from hydrogenosomes of Trichomonas vaginalis: purification and characterization / T. Drmota, P. Proost, M. Van Ranst // J. Mol. Biochem. Parasitol. – 1996. – Vol. 83, № 2. – P. 221–234.
22. Steinbüchel A. Anaerobic pyruvate metabolism of Tritrichomonas foetus and Trichomonas vaginalis
23. hydrogenosomes / A. Steinbüchel, M. Müller // Mol. Biochem. Parasitol. – 1986. – Vol. 20, № 1. – P. 57–65.
24. Williams K. Purification and characterization of pyruvate: ferredoxin oxidoreductase from the anaerobic protozoon Trichomonas vaginalis / K. Williams, P.N. Lowe, P.F. Leadlay // J. Biochem. – 1987. – Vol. 246, № 2. – P. 529–536.
25. Hrdy I. Primary structure and eubacterial relationships of the pyruvate: ferredoxin oxidoreductase of the amitochondrial eukaryote Trichomonas vaginalis / I. Hrdy, M. Muller // J. Mol. Evol. – 1995. – Vol. 41, № 3. – P. 388–396.
26. Jenkins T.M. Hydrogenosomal succinate thiokinase in Tritrichomonas foetus and Trichomonas vaginalis / T.M. Jenkins, T.E. Gorrell, M. Muller // Biochem.Biophys.Res. Commun. – 1991. – Vol. 179, № 2. – P. 892–896.
27. Lathi C.J. Molecular characterization of the a-subunit of Trichomonas vaginalis hydrogenosomal succinyl CoA synthetase / C.J. Lathi, P. Bradley, P.J. Johnson // Mol. Biochem. Parasitol. – 1994. – Vol. 66. – P. 309–318.
28. Marczak R. Hydrogenosomal ferredoxin of the anaerobic protozoon Tritrichomonas foetus / R. Marczak, T.E. Gorrell, M. Muller // J. Biol. Chem. – 1983. – Vol. 258, № 20. – P. 12427–12433.
29. Johnson P.J. Molecular analysis of the hydrogenosomal ferredoxin of the anaerobic protist Trichomonas vaginalis / P.J. Johnson, C.E. Oliveira, T.H. Gorrell // Proc. Natl. Acad. Sci.USA. – 1990. – Vol. 87, №16. – P. 6097–6101.
30. Ings, R.M. The mode of action of metronidazole in Trichomonas vaginalis and other microorganisms / R.M. Ings, J.A. McFadzean, W.E. Ormerod // Biochem.Pharmacol. – 1974. – Vol. 23. – P. 1421–1429.
31. Muller M. Energy metabolism of ancestral eukaryotes: a hypothesis based on the biochemistry of amitochondriate parasitic protists / M. Muller // Chin.Med.J. – 1992. – Vol. 28, №1–3. – P. 33–40.
32. Tocher J.H. Electrochemical characteristics of nitroheterocyclic compounds of biological interest. IV. Lifetime of the metronidazole radical anion / J.H. Tocher, D.I. Edwards // Free Radical Research Communications. – 1989. – Vol. 6. – P. 39–45.
33. Rowley D.A. The relationship between misonidazole cytotoxicity and base composition of DNA / D.A. Rowley, R.C. Knight, I.M. Skolimowski // Biochem.Pharmacol. – 1980. – Vol. 29, № 15. – P. 2095–2099.
34. Knox R.J. Misonidazole-induced thymine release from DNA / R.J. Knox, R.C. Knight, D.I. Edwards // Biochem. Pharmacol. – 1981. – Vol. 30, №14. – P. 1925–1929.
35. Jennison R.F. Laboratory studies with the systemic trichomonacide, metronidazole / R.F. Jennison, P. Stenton, L. Watt // J. Clin. Pathol. – 1961. – Vol. 14. – P. 431–435.
36. Csonka G.W. Trichomonal vaginitis treated with one dose of Metronidazole / G.W. Csonka // Brit. J. Vener. Dis. – 1971. – Vol. 47. – P. 456.
37. Wisdom A.R. Trichomoniasis study of the disease and its treatment / A.R. Wisdom, E.M.C. Dunlop // Brit. J. Vener. Dis. – 1965. – Vol. 41. – P. 90.
38. Morton R.S. Metronidazole in the single-dose treatment of trichomoniasis in men and women / R.S. Morton // Brit. J. Vener. Dis. – 1972. – Vol. 48. – P. 525.
39. Cohen L. Nitrimidazine in the treatment of Trichomonas vaginalis vaginitis / L. Cohen // Brit. J. Vener. Dis. – 1971. – Vol. 47. – P. 177.
40. Wallin J. Tinidazole-a new preparation for T. vaginalis Infections / J.Wallin A. Forsgren // Brit. J. Vener. Dis. – 1974. – Vol. 50. – P. 148.
41. Lean T.H. Treatment of vaginal trichomoniasis with a new anti-protozoal compound (cc-chloromethyl-2-methyl-5- nitro- 1 -imidazole-ethanol) / T.H. Lean, D. Vengadasalam // Brit.J.Vener.Dis. – 1973. – Vol. 49. – P. 69.
42. Robinson S.C. Trichomonal vaginitis resistant to metronidazole / S.C. Robinson // J. Canad. Med. Ass. –1962. – Vol. 86. – P. 665.
43. Squires S. Strain sensitivity of Trichomonas vaginalis to metronidazole / S. Squires J. A. McFadzean // Brit. J. Vener. Dis. – 1962. – Vol. 38. – P. 218.
44. Кovacs Elek dr. A Trichomonas vaginalis törzsek metronidazol erzekenysegeröl / E. Кovacs, J. Galgoszy //Orvosi Hetilap. – 1968. – Vol. 110. – P. 66–-68.
45. Cтаростина З.Д. Чувствительность трихомонады к флагилу и ее значение в лечении трихомонадной инфекции у женщин / З.Д. Cтаростина // Вестник дерматологии и венерологии. – 1973. – № 10. – С. 84–85.
46. Корик Л.М. О штаммах Trichomonas vaginalis резистентных к метронидазолу / Л.М. Корик / Вестник дерматологии и венерологии. – 1971. – № 12. – С. 77–79.
47. Hayward M.J. Two-day treatment of trichomoniasis in the female. Comparison of metronidazole and nimorazole /M.J. Hayward, R.B. Roy // Br. J. Vener. Dis. – 1976. – Vol. 52, №1. – P. 63–64.
48. Kulda J. Experimental animals in studies of T. vaginalis infection / B.M. Honigberg // Trichomonads parasitic in humans – New York.: Springer-Verlag. – P. 112–153.
49. Lossick J.G. Therapy of urogenital trichomoniasis /B.M. Honigberg // Trichomonads parasitic in humans - New York.: Springer-Verlag. – P. 324–341.
50. Kulda J. Trichomonads: hydrogenosomes and drug resistance / J. Kulda // International Journal for Parasitology. – 1999. – Vol. 29, №2. – P. 199–212.
51. Cerkasovova A. Metabolic properties of Trichomonas vaginalis resistant to metronidazole under anaerobic conditions / A. Cerkasovova, J.Novak, J. Cerkasov // Acta. Univ.Carolinae.Biol. – 1988. – Vol. 30. – P. 505–512.
52. Leitsch D. The flavin inhibitor diphenyleneiodonium renders Trichomonas vaginalis resistant to metronidazole, inhibits thioredoxin reductase and flavin reductase, and shuts off hydrogenosomal enzymatic pathways / D. Leitsch, D. Kolarich, M. Duchêne // Mol.Biochem.Parasitol. – 2010. – Vol. 171, № 1. – Р. 17–24.
53. Клименко Б.В. Трихомониаз мужчин, женщин и детей / Б.В. Клименко, Э.Р. Авазов, В.Б. Барановская, М.С. Степанова. – СПб.: Сюжет, 2001. – 192 с.
54. Самохин В.Л. Морфология Trichomonas vaginalis и современные противотрихомонадные лекарственные средства/ В.Л. Самохин // ИППП. – 2002. – №5. – С. 15–18.
55. Nielsen M. H. In vitro effect of metronidazole on the ultrastructure of Trichomonas vaginalis Donne / M.H. Ni el sen // Ac ta Pathol. Microbiol. – 1976. – Vol. 84. – P. 93–100.
56. Peterson K. M. Acquisition of alpha 1-Antitrypsin by a pathogenic strain of Trichomonas vaginalis / K. M. Peterson, J.F. Alderete // Infect. Immun.- 1983. – Vol. 40, № 2. – P. 640–646.
57. Захаркив Ю.Ф. Сравнительная оценка чувствительности Trichomonas vaginalis к препаратам 5-нит роимидазольного ряда и других групп in vitro и in vivo и контроль эффективности этиотропной терапии/ Ю.Ф. Захаркив, С.С. Козлов, А.Ф. Никитин с соавт. // Фарматека. –2008. - №9. – С. 48–52.
Review
For citations:
Poznyak A.L., Kozlov S.S., Gudkov R.V., Zaharkiv Yu.F., Sidorchuk S.N., Molchanov O.L. The problem of resistant Trichomonas vaginalis to antiprotozoal drugs. Journal Infectology. 2011;3(4):34-43. (In Russ.) https://doi.org/10.22625/2072-6732-2011-3-4-34-43